AIGH Capital Management’s Cognition Therapeutics CGTX Stock Holding History

AIGH Capital Management’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-300,766	Closed	-$499K	–	41
2024 Q2	$499K	Sell	300,766 -1,596,507	-84%	-$3.18M	0.16%	35
2024 Q1	$3.45M	Sell	1,897,273 -141,580	-7%	-$292K	1.04%	28
2023 Q4	$3.77M	Hold	2,038,853	–	–	1.49%	26
2023 Q3	$2.94M	Hold	2,038,853	–	–	1.39%	20
2023 Q2	$3.73M	Buy	2,038,853 +1,000	+0%	+$2.12K	1.52%	19
2023 Q1	$4.03M	Hold	2,037,853	–	–	1.49%	20
2022 Q4	$4.28M	Buy	2,037,853 +1,239,518	+155%	+$2.5M	1.41%	21
2022 Q3	$1.52M	Sell	798,335 -112,455	-12%	-$234K	0.47%	32
2022 Q2	$2.38M	Buy	+910,790	New	+$2.35M	0.63%	25
2022 Q1	–	Sell	-25,496	Closed	-$161K	–	44
2021 Q4	$161K	Buy	+25,496	New	+$249K	0.05%	50

Other funds holding CGTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

AFG

American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AIGH Capital Management's CGTX Position: Q3 2024 in Review

AIGH Capital Management sold out of Cognition Therapeutics (CGTX) in Q3 2024, closing a stake of 300,766 shares — an estimated $499K sold.

AIGH Capital Management first reported a position in CGTX in Q4 2021 and held it in 10 quarters. The position peaked at $4.28M in Q4 2022. 40 funds tracked by Wall St. Rank hold CGTX as of Q3 2024.

AIGH Capital Management reported no remaining Cognition Therapeutics position as of Q3 2024 after selling out during the quarter.
AIGH Capital Management sold 300,766 Cognition Therapeutics shares in Q3 2024, an estimated $499K.
AIGH Capital Management first reported a position in Cognition Therapeutics in Q4 2021 and held it in 10 quarters.
AIGH Capital Management's Cognition Therapeutics position peaked at $4.28M in Q4 2022.
40 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2024.

Based on AIGH Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.